ICICI Prudential Asset Managment Co. Ltd IPO : Subscribe

  • Date

    12th Dec 2025 - 16th Dec 2025

  • Price Range

    Rs.2061 to Rs 2165

  • Minimum Order Quantity

    06

Price Lot Size Issue Date Issue Size
₹2061 to ₹2165 6 12th Dec, 2025 –16th Dec, 2025 ₹10602.65 Cr

ICICI Prudential Asset Managment Co. Ltd

ICICI Prudential Asset Management Company, one of the oldest fund houses in India with a legacy of over 30 years, has operated as a joint venture between ICICI Bank and Prudential Corporation Holdings Limited since 1998. Over the years, it has established a leadership position in the industry, and as of September 30, 2025, it is the largest asset manager in the country by active mutual fund QAAUM, equity and equity-oriented QAAUM (Quarterly Average Assets Under Management), hybrid QAAUM, and individual investor MAAUM. The company serves a vast customer base of 15.5 million investors, offering a comprehensive suite of 143 schemes across equity, debt, passive, fund-of‑funds, liquid, overnight, and arbitrage categories, making it the most diversified scheme manager in the Indian mutual fund industry. Alongside its core mutual fund franchise, ICICI Prudential AMC has steadily expanded its “Alternates” business, which includes portfolio management services, alternative investment funds, and offshore advisory, thereby broadening its product range and strengthening its presence in higher-yield segments. Its investment philosophy has consistently emphasised disciplined risk management and long-term wealth creation, helping the brand remain trusted and resilient throughout market cycles. The company has established a pan-India presence with 272 offices across 23 states and four union territories, supported by a balanced multi-channel distribution model that combines physical reach with digital platforms and a strong salesforce. In recent years, it has modernized its technology infrastructure through cloud adoption, launched redesigned websites and a mobile app with simplified navigation, and improved distributor portals with enhanced features, all aimed at enhancing investor experiences and operational efficiency. Collectively, these strengths position ICICI Prudential AMC as a market leader with scale, diversity, and innovation at the core of its story.

Objective of the ICICI Prudential Asset Managment Co. Ltd IPO

The company will not receive any proceeds from the offer.

Rationale To ICICI Prudential Asset Managment Co. Ltd IPO

Diversified product portfolio across asset classes

The company relies on its well-diversified product range to meet diverse customer needs and risk-return profiles, while effectively adapting to shifting economic conditions. As of September 30, 2025, it managed 143 mutual fund schemes, the highest number in India. No single scheme accounts for more than 7.1% of mutual fund QAAUM, ensuring diversification and stability. The company has consistently led in product innovation, creating differentiated offerings tailored to long-term investor objectives across various market conditions. Beyond mutual funds, it provides portfolio management services, manages AIFs, and offers offshore advisory. PMS clients benefit from strong risk and governance standards with a personalised, boutique approach, while the AIF business has expanded driven by investor demand for distinctive strategies and proven expertise. The company also advises Eastspring, Prudential’s asset management arm, on select equity and debt products distributed across Japan, Taiwan, Hong Kong, and Singapore. This diverse portfolio highlights its ability to serve a broad range of investor needs while maintaining leadership in innovation and global presence.

Pan-India, multi-channel and diversified distribution network

The company has established a pan-India distribution network of 272 offices across 23 states and four union territories, designed to be balanced and multi-channel, covering both physical and digital platforms supported by its salesforce. As of September 30, 2025, this network included 1,10,719 institutional and individual MFDs, 213 national distributors, and 67 banks, including ICICI Bank. Utilising its parent’s reach, ICICI Bank serves customers through 7,246 branches nationwide. Alongside its physical presence, the company maintains a strong digital ecosystem with its website and mobile app ‘i-Invest’. Digital adoption has grown rapidly, with 11.0 million mutual fund purchase transactions in H1FY26 and 20.9 million in FY25, up from 10.1 million in FY23. Notably, in H1FY26, 95.3% of transactions were executed digitally. The company also engages potential investors through social media content marketing, which has attracted 1.2 million new customers in H1FY26, demonstrating the effectiveness of its multichannel model.

Valuation of ICICI Prudential Asset Managment Co. Ltd IPO

The company’s valuation strength is based on its leadership across asset management categories and consistent profitable growth. As of September 30, 2025, it was the largest asset manager in India with a 13.3% share of active mutual fund QAAUM, 13.6% in equity and equity-oriented QAAUM, and 25.8% in equity-oriented hybrid QAAUM. Equity and equity-oriented QAAUM increased to Rs. 4,876 billion, achieving a 40% CAGR over FY23-25, surpassing the industry’s 36% growth. This equity-heavy mix, which has higher fee structures than non-equity schemes, has supported superior operating profitability. The company also leads in individual investor assets, with mutual fund MAAUM of Rs. 6,610 billion and a 13.7% market share as of September 30, 2025. Individual investors accounted for 61% of total mutual fund MAAUM and 86% of equity- and equity-oriented scheme MAAUM, indicating a preference for higher-fee equity products. Systematic flows provide resilience and predictability, with monthly inflows increasing to Rs. 48.0 billion in September 2025 from Rs. 23.5 billion in March 2023. Of the 15.5 million individual investors, 6.4 million held at least one systematic transaction folio, emphasising the depth of engagement and long-term stability. Between FY23-25, AAUM, operating revenue, and PAT grew at CAGRs of 32.7%, 32.0%, and 32.2%, respectively. Capital efficiency remains exceptional, with an annualised ROE of 86.8% in FY2025 and 82.8% for H1FY26. At the upper end of the price band of Rs. 2,165 per share, the issue is valued at a P/E of 40.4x based on FY25 earnings. The valuation is broadly in line with other large listed asset management companies, making the multiple justified. Supported by industry leadership, strong profitability, and sustained value creation, we recommend a “Subscribe” rating for this issue.

What is the ICICI Prudential Asset Managment Co. Ltd IPO?

The initial public offer (IPO) of ICICI Prudential Asset Managment Co. Ltd offers an early investment opportunity in ICICI Prudential Asset Managment Co. Ltd . A stock market investor can buy ICICI Prudential Asset Managment Co. Ltd IPO shares by applying in IPO before All ICICI Prudential Asset Managment Co. Ltd shares get listed at the stock exchanges. An investor could invest in ICICI Prudential Asset Managment Co. Ltd IPO for short term listing gain or a long term.

To apply for the ICICI Prudential Asset Managment Co. Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

ICICI Prudential Asset Managment Co. Ltd IPO is opening on 12th Dec 2025.  Apply Now

The Lot Size of ICICI Prudential Asset Managment Co. Ltd IPO is 06 equity shares. Login to your account now.

The allotment Date for ICICI Prudential Asset Managment Co.Ltd IPO is 17th Dec 2025.  Login to your account now.

The listing Date for ICICI Prudential Asset Managment Co.Ltd IPO is 19th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 12,990. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,94,850. Login to your account now

  • The company’s performance is sensitive to market and economic conditions. Downturns or weak product performance could reduce AUM, fee income, and cash flows.
  • Intense competition, dependence on promoter brand reputation, and the risk of counterparties terminating agreements make future growth and revenues unpredictable; These factors coupled with challenges in scaling new products, could materially impact market share, profitability, and long-term sustainability.
  • Operating in a regulated industry, the company faces risks from policy changes, compliance lapses, cyber-attacks, credit losses, and contingent liabilities that could disrupt operations and financials.
  • The performance of the company’s equity-oriented schemes has a significant impact on its assets under management (AUM) and consequently its revenue from operations. Any underperformance in performance could disproportionately impact business and earnings.

The ICICI Prudential Asset Managment Co.Ltd IPO be credited to the account on allotment date which is 18th Dec 2025. Login to your account now 

The prospectus of ICICI Prudential Asset Managment Co.Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Vidya Wires Ltd IPO : Subscribe

  • Date

    03rd Dec 2025 - 05th Dec 2025

  • Price Range

    Rs.48 to Rs 52

  • Minimum Order Quantity

    288

Price Lot Size Issue Date Issue Size
₹48 to ₹52 288 03rd Dec, 2025 –05th Dec, 2025 ₹300.01 Cr

Vidya Wires Ltd

Based out of Gujarat, Vidya Wires Ltd. (VWL) is involved in the manufacturing of insulated copper and aluminum wires that are used across wide range of industries like energy generation & transmission, electrical systems, electric motors, clean energy systems, electric mobility, and railways. Their product portfolio includes precision-engineered Enameled Wires, Enameled Copper Rectangular Strips, Paper Insulated Copper Conductors, Copper Busbar and Bare Copper Conductors, Specialized Winding Wires, PV Ribbon and Aluminum Paper Covered Strips, among others. With an annual capacity of 19,680 MT, the company ranks as the fourth largest manufacturer in the industry, with a market share of 5.7% of installed capacity in FY25. Their manufacturing facilities are strategically located near the ports of Hazira and Mundra, providing a logistical advantage for exports. VWL is a pre-approved supplier to Power Grid Corporation of India Ltd. and also holds UL approval, enabling it to export enameled copper and aluminum wire to the US. In Q1FY26, revenue comprised 88% domestic sales, 11% exports, with the remainder coming from other operations, hinting towards more focus on the domestic market as also outlined by the management. The company offers a diverse portfolio of winding and conductivity products across 12 product categories with over 8,000 SKUs, with sizes ranging from as thin as 0.07 mm to as thick as 25 mm. With its wide product range, the company is able to serve customers across 19 Indian states and union territories, with Gujarat and Maharashtra contributing 69% of revenue in Q1FY26. With focus on the environment, the company has fulfilled 25% of power requirements from renewable sources like solar and windmills in Q1FY26.

Objective of the Vidya Wires Ltd IPO

The company proposes to utilize net proceeds from the issue towards the following objects:

  1. Funding capital expenditure requirements for setting up new project in its subsidiary viz. ALCU ;
  2. Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the company; and
  3. General corporate purposes.

Rationale To Vidya Wires Ltd IPO

Capacity expansion and increased product offering to significantly enhance market share

With an existing installed capacity of 19,680 MT per annum, the company intends to deploy IPO proceeds towards an additional 18,000 MT per annum, raising cumulative capacity to 37,680 MT. The expansion is scheduled for commissioning by Q3FY26, positioning the company as India’s third-largest manufacturer by installed capacity. Currently, the company has 12 product categories with over 8,000 SKU and intends to introduce 6 additional categories through this expansion, targeting evolving demand and improved customer stickiness. The company intends to add new products like copper foils, copper components, continuously transposed copper conductors, PV round ribbon, solar cables, multi paper covered copper conductors, enameled aluminium winding wires, and enameled aluminium rectangular strips to its current product portfolio. This strategic expansion comes after existing two units reach near optimum capacity utilisation. In Q1FY26, Unit 1 operated at a utilization rate of 80%, up from 57% in FY23, while Unit 2 operates at 97%, up from 72% in FY23. This is a testament to the rising demand as India’s copper and aluminium wiring industry is set for steady growth, driven by electric vehicle adoption, renewable energy investments, and large-scale infrastructure projects. The sector is projected to grow steadily, with products such as enamelled copper winding wire, paper-covered aluminium conductors, PV ribbons, and solar PVC cables fuelling sales. Transformers are one of the key end-use industries driving growth in the copper sector. With rising power demand and the rapid adoption of renewable energy, India requires a stronger and wider power grid for distribution and as this ecosystem is heavily dependent on copper, it provides a strong tailwind that is expected to drive growth. According to the management guidance, this capacity expansion and increased product offering is expected to double VWL’s market share from 5.7% to 11.3%.

De-risked business with diversified supplier and customer base along with in-built hedging mechanism shielding margins

Over FY2023-25 period, the company served over 318 customers, including over 19 international customers in more than 18 countries across 5 continents including the US, Saudi Arabia, UAE, Australia, Canada, Egypt, Singapore, etc. with none of its customer singly contributing over 9% of annual revenues. VWL serves broad industry base, with power & transmission contributing 49%, electrical 22%, renewable EV & automotive 11%, general engineering 10%, and consumer durables 8% in Q1FY26. While the mix has remained stable over the past three years, renewables have shown a notable increase from 7% in FY23 to 11% in Q1FY26. Going forward, the company expects a higher revenue share from this segment, as aluminium product sales in renewables and EVs are expected to drive margin improvement. Over the years, VWL has developed relationships with its customers including Adani Wilmar, Transformers & Rectifiers (India), Schneider Electric Infrastructure, etc., which have shown high stickiness as evident by 80% of business coming from repeat customers. On the supply side, out of total requirement of copper rods, about 35%-40% was manufactured in-house from copper cathodes and the remaining was purchased from external suppliers evenly split between Vedanta Ltd., Marubeni Corporation and Union Copper rod. The raw material requirement is balanced, with a 50:50 split between domestic and imported supplies, thereby reducing supply chain risks. To mitigate the risk of copper price volatility, the company employs a no-cost hedging mechanism wherein raw material supply is booked only after customer orders are confirmed at prices quoted on the London Metal Exchange, thereby shielding margins. 

Valuation of Vidya Wires Ltd IPO

Vidya Wires Ltd. (VWL), based out of Gujarat, manufactures insulated copper and aluminum wires used across industries such as energy, electrical systems, clean energy, EVs, and railways. With an annual capacity of 19,680 MT and planned expansion to 37,680 MT (+18,000 MT), ranking it the third largest manufacturer in the industry. It currently holds a 5.7% market share which is expected to double to 11.3%, driven by capacity expansion and addition of six new product categories serving customers across 19 states, with Gujarat and Maharashtra contributing 69% of Q1FY26 revenue. Manufacturing facilities near Hazira and Mundra ports provide export advantages to the company. On the financial front, the company delivered a revenue growth of 21% over FY2023-25 period to reach Rs. 1,486 crores. For FY25, the EBITDA margin of peers ranged between 3% and 5%, while VWL showed a steady growth increasing from 3.5% in FY23 to 4.3% in FY25. The margins are expected to improve, with the increase in revenue contribution from high margin business of EV and renewables. The company delivered a robust PAT growth of 38% CAGR over FY2023-25 period. Return ratios remained healthy, with RoE at 25% (peer average 15%) and RoCE at 20% (peer average 21%) in FY25. Historically, the company maintained a consistent debt to equity ratio around 0.9x, with fixed asset turnover reaching a high of 36x in FY25. At the upper end of the price band of Rs. 52 per share, the issue is valued at a P/E of 27.1x based on FY25 earnings, which appears highly lucrative given the industry average is 37x. Given strong growth prospects and planned expansion, we recommend a “SUBSCRIBE” rating for this issue.

What is the Vidya Wires Ltd IPO?

The initial public offer (IPO) of Vidya Wires Ltd offers an early investment opportunity in Vidya Wires Ltd . A stock market investor can buy Vidya Wires Ltd IPO shares by applying in IPO before All Vidya Wires Ltd shares get listed at the stock exchanges. An investor could invest in Vidya Wires Ltd IPO for short term listing gain or a long term.

To apply for the Vidya Wires Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Vidya Wires Ltd IPO is opening on 03rd Dec 2025.  Apply Now

The Lot Size of Vidya Wires Ltd IPO is 288 equity shares. Login to your account now.

The allotment Date for Aequs Ltd IPO is 08th Dec 2025.  Login to your account now.

The listing Date for Vidya Wires Ltd IPO is 10th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,976. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,94,688. Login to your account now

  • Execution Risk: Timely commissioning of the planned 18,000 MT capacity expansion by Q3FY26 is critical; any delays or cost overruns could impact growth and market share targets.
  • Industry Dependence: Heavy reliance on copper and aluminum wiring demand from EVs, renewables, and infrastructure projects means any slowdown in these sectors could affect revenue growth and margins.

The Aequs Ltd IPO be credited to the account on allotment date which is 09th Dec 2025. Login to your account now 

The prospectus of Vidya Wires Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Nephrocare Health Ltd IPO : Subscribe

  • Date

    10th Dec 2025 - 12th Dec 2025

  • Price Range

    Rs.438 to Rs 460

  • Minimum Order Quantity

    32

Price Lot Size Issue Date Issue Size
₹438 to ₹460 32 10th Dec, 2025 –12th Dec, 2025 ₹871.00 Cr

Nephrocare Health Ltd

Nephrocare Health Services offers comprehensive dialysis care through its network of clinics, from diagnosis and treatment to wellness programs, including haemodialysis, home and mobile dialysis, and a pharmacy. The company also provides holiday dialysis, on-call dialysis, and dialysis-on-wheels services to its patients in India. The company is India’s largest dialysis service provider, based on the number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA in FY25. Further, the company is 4.4 times the size of the next-largest organized dialysis provider in India, based on operating revenue in FY24. In FY25, the company served 29,281 patients and completed 2,885,450 treatments in India, which represented ~10% of the total dialysis patients in India. The company operates 519 clinics, forming India’s most extensive dialysis network, with a presence across 288 cities in 21 States and 4 Union Territories as of September 30, 2025. 77.4% of its clinics are located in tier II and tier III cities and towns. As of September 30, 2025, 80 clinics operated through greenfield, 259 through brownfield, and 180 via PPP collaborations. The company has partnered with leading hospital chains in India, including Max Super Specialty Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital and Grand Medical Foundation (Ruby Hall) to operate specific dialysis clinics. The company is the leader in dialysis services in FY25, with a market share of over 50% in the organised market (by number of treatments) and ~50% in revenue generated by organiZed dialysis service providers. The company’s clinics are accredited by leading bodies in India, with 145 of its dialysis clinics accredited by NABH and three by JCI as of September 30, 2025. The company also complies with ISO standards ISO 9001:2015 for quality management systems.

Objective of the Nephrocare Health Ltd IPO

Out of the total issue size of Rs. 871 crores, Rs. 518 crores comprises OFS.

The company proposes to utilize net proceeds from the issue towards the following objects:

  • Capital expenditure by company for opening new dialysis clinics in India and;
  • Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by company; and
  • General corporate purposes. 

Rationale To Nephrocare Health Ltd IPO

Strong market presence as India and Asia’s largest dialysis provider

The company is India’s largest dialysis service provider in terms of the number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA (excluding other income) in FY25, and it is 4.4 times the size of the next largest organized dialysis provider in India in terms of operating revenue in FY24. The company was also the largest dialysis service provider in Asia in 2025 and the fifth-largest globally based on the number of treatments performed in FY25. In India, the company is the leader in dialysis services in FY25, with a market share of over 50% in the organized dialysis market (by number of treatments) and ~50% in revenue generated by organized dialysis service providers. As of September 30, 2025, the company has performed over 1.87 million treatments, with the number of treatments growing at a CAGR of 20.1% between FY23 and FY25. Additionally, as of September 30, 2025, the company had 5,562 dialysis machines, up from 5,068, 4,714, and 3,662 as of March 31, 2025, March 31, 2024, and March 31, 2023, respectively. As of September 30, 2025, the company operated clinics in 3 countries other than India. The company commenced international operations in 2018 with its entry into Nepal, an extension of its cluster-based approach in India. The company entered the Philippine market in October 2020, following its acquisition of a majority stake in Royal Care Dialysis Centre Inc. (RCDC) and Asialife Healthcare Corp (Asialife). Through these acquisitions, the company gained access to RCDC’s and Asialife’s network of six clinics across the Philippines. Over the next 2 years, the company subsequently acquired 100% ownership of RCDC and expanded its footprint to 10 clinics. As of September 30, 2025, the company operated 51 clinics in the Philippines. The company was the 3rd-largest dialysis service provider in the Philippines by the number of clinics in 2024. The company won a USD 75+ million PPP tender issued by the Ministry of Health, Republic of Uzbekistan, to establish four clinics, including a 165-bed dialysis clinic in Tashkent, the largest dialysis clinic globally.

Scale, coupled with an asset-light model, drives cost efficiencies and operational excellence

The company has expanded from a single clinic in India in 2010 to 519 clinics across India, Nepal, the Philippines, and Uzbekistan as of September 30, 2025, with a presence in 328 cities. Its growth strategy combines greenfield and brownfield operations with PPP collaborations, enabling efficient scaling and diverse patient coverage. As of September 30, 2025, 80 clinics operated through greenfield, 259 through brownfield, and 180 via PPP collaborations. The company follows an asset-light model, enabling lower establishment and operating costs compared to tertiary care and other single-speciality services. As of September 30, 2025, 52.4% of its 519 clinics operate on a revenue-sharing model with limited space investment, reflecting its commitment to lean operations. Initiatives such as standardized clinic formats, an in-house projects team, and an efficient supply chain have helped reduce capital expenditure and keep establishment costs low. In the 6 months ended September 30, 2025, and FY25, FY24, and FY23, capital expenditure per clinic was Rs. 1.0 crores, Rs. 1.4 crores, Rs. 1.7 crores, and Rs. 1.1 crores, respectively. The company uses a cluster-based approach to expand its network, starting with clinics in densely populated areas and then growing within cities and nearby towns. Expansion is guided by catchment demographics, market dynamics, and backend infrastructure, with clinic selection based on demand-supply gaps, nephrologist availability, dialysis volumes, government schemes, and due diligence. This approach has enabled operations in non-metro, tier II, and tier III locations, improving accessibility. As of September 30, 2025, the company had 128 clinics in tier II and 234 in tier III cities.

Valuation of Nephrocare Health Ltd IPO

The company is India’s largest dialysis service provider, with market leadership across key metrics including patients served, clinics, cities covered, treatments performed, revenue, and EBITDA in FY25. Its scale advantage is significant, being 4.4 times larger than the next-largest organized player in terms of operating revenue in FY24. With operations spanning India and international markets, including Nepal, the Philippines (51 clinics), Uzbekistan, and KSA, the company has established itself as the largest dialysis chain in Asia and the fifth-largest globally, based on treatments performed in FY25. The company has also built a highly scalable hub-and-spoke model, anchored in an asset-light approach, in which it partners with hospitals and public health authorities to expand its clinic footprint without significant upfront capital. This allows rapid market entry, superior cost efficiency, and substantial operating leverage as patient volumes scale. Its international acquisitions have enabled the company to diversify revenue streams, deepen regional penetration, and replicate its successful cluster-based India strategy across Asia. India’s dialysis market is structurally expanding due to rising CKD prevalence, increasing prevalence of lifestyle diseases, limited access to renal care in Tier-II/III cities, and low penetration of organized dialysis networks. The organized dialysis segment is rapidly gaining share as government programs, insurance coverage, and PPP-driven models expand patient access to affordable, reliable services. On the financial front, the company has demonstrated CAGR growth of 31.5%/85.2% in Revenue/EBITDA between FY23 and FY25, driven by rapid network expansion, rising treatment volumes, and improving revenue per treatment, supported by acquisitions, new clinic openings, and scale benefits. Overall, the company is well-positioned to sustain its growth trajectory, driven by continued clinic additions, further penetration into underserved regions, and scaling of international operations. At the upper end of the price band at Rs. 460, the company is valued at a P/E multiple of 57.4x FY25 earnings. We, thus, recommend a “SUBSCRIBE” rating for this issue.

What is the Nephrocare Health Ltd IPO?

The initial public offer (IPO) of Nephrocare Health Ltd offers an early investment opportunity in Nephrocare Health Ltd . A stock market investor can buy Nephrocare Health Ltd IPO shares by applying in IPO before All Nephrocare Health Ltd shares get listed at the stock exchanges. An investor could invest inNephrocare Health Ltd IPO for short term listing gain or a long term.

To apply for the Nephrocare Health Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Nephrocare Health Ltd IPO is opening on 10th Dec 2025.  Apply Now

The Lot Size of Nephrocare Health Ltd IPO is 32 equity shares. Login to your account now.

The allotment Date for Nephrocare Health Ltd IPO is 15th Dec 2025.  Login to your account now.

The listing Date for Nephrocare Health Ltd IPO is 17th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,720. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,91,360. Login to your account now

  • A significant share of company’s revenue comes from captive clinics within private hospitals. Any cancellation or non-renewal of these contracts could materially disrupt operations and adversely impact our revenue and financial performance.
  • A meaningful portion of company’s revenue is derived from PPP contracts awarded through competitive government bidding. Any inability to qualify for, win, or renew such tenders could reduce revenue visibility and adversely affect our business prospects, financial performance, and cash flows.
  • The company exposed to operational, medical, legal, and reputational risks inherent in delivering dialysis services. Any failure to maintain required quality standards could lead to patient harm, litigation, and reputational damage, materially impacting operations and financial performance.  

The Nephrocare Health Ltd IPO be credited to the account on allotment date which is 15th Dec 2025. Login to your account now 

The prospectus of Nephrocare Health Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Park Medi World Ltd IPO : Subscribe

  • Date

    10th Dec 2025 - 12th Dec 2025

  • Price Range

    Rs.154 to Rs 162

  • Minimum Order Quantity

    92

Price Lot Size Issue Date Issue Size
₹154 to ₹162 92 10th Dec, 2025 –12th Dec, 2025 ₹920.00 Cr

Park Medi World Ltd

The company is the second-largest private hospital chain in North India, with a total bed capacity of 3,000, and the largest in Haryana, operating 1,600 beds in the state as of March 31, 2025. Its network comprises 14 NABH-accredited multispecialty hospitals under the ‘Park’ brand across Haryana, Delhi, Punjab, and Rajasthan, offering more than 30 specialty and super-specialty services, including internal medicine, neurology, urology, gastroenterology, orthopedics, and oncology. As of September 30, 2025, the organization employs over 1,000 doctors and 2,100 nurses dedicated to delivering high-quality clinical care. Founded by Dr. Ajit Gupta, who established the Park Hospital brand in 2005, the company has grown significantly through strategic expansions and the acquisition of eight hospitals across North India, increasing its bed capacity from 2,550 to 3,250 within two years. Its expansion pipeline includes new projects in Ambala, Panchkula, Rohtak, Gorakhpur, and Kanpur, with a projected increase in total capacity to 4,900 beds by 2028. The company is also in the process of acquiring Durha Vitrak (Febris Multi-Specialty Hospital, New Delhi) and has a long-term agreement to operate a 400-bed hospital in Gorakhpur. Its hospitals are equipped with advanced clinical infrastructure, including 870 ICU beds, 67 operating theatres, dedicated cancer units with linear accelerators, and specialized Institutes for Minimal Access and Robotic Surgery (iMARS).

Objective of the Park Medi World Ltd IPO

Out of the total issue size of Rs. 920 crores, Rs. 150 crores comprises OFS.

The company proposes to utilize net proceeds from the issue towards the following objects:

  • Repayment/ prepayment, in full or in part, of outstanding borrowings availed by company and Subsidiaries;
  • Funding capital expenditure for development of new hospital by Subsidiary, Park Medicity (NCR);
  • Funding capital expenditure for purchase of medical equipment by company and Subsidiaries, Blue Heavens and Ratangiri; and
  • Unidentified inorganic acquisitions and general corporate purposes.

Rationale To Park Medi World Ltd IPO

North India’s second-largest private hospital chain, anchored by Haryana market leadership

The company’s position as the second-largest private hospital chain in North India and the largest in Haryana provides a strong foundation for sustainable long-term growth. With an aggregate bed capacity rising from 2,550 beds in FY23 to 3,250 beds as of September 30, 2025, the company has demonstrated consistent expansion through a combination of organic growth and strategic acquisitions. Its cluster-based approach, establishing hospitals in adjacent geographies, has enabled brand reinforcement, resource sharing, and meaningful operating leverage. The network today comprises 14 NABH-accredited multi-super specialty hospitals equipped with 870 ICU beds, 67 operating theatres, dedicated cancer units, trauma centers, and oxygen generation plants, underscoring strong clinical infrastructure and capability. Five hospitals are also approved for kidney transplant procedures, reflecting competency in high-acuity care. With operations concentrated in North India, a region characterized by significant under-penetration of healthcare infrastructure and low doctor, nurse, and bed availability, the company is strategically positioned to capture a disproportionate share of regional demand. Supported by favorable industry tailwinds, including rising demand for routine and elective procedures and a healthcare delivery market projected to grow at a 10-12% CAGR through FY29, the company stands to benefit from scale, brand strength, and increasing demand for quality yet affordable healthcare. The company’s entrenched leadership in North India provides a strategic platform to tap into sizeable market opportunities and drive scale efficiencies, all while preserving the quality standards central to its healthcare delivery model.

High-quality, affordable healthcare across a diverse specialty network

The company operates with a clear vision of delivering high-quality healthcare at affordable rates, primarily serving lower- and middle-income patients across its extensive hospital network. Its focus on affordability is supported by disciplined cost optimization measures, including the use of advanced medical technologies that shorten patient recovery times, a predominantly full-time clinical workforce, strong vendor partnerships, and the operating leverage generated from its growing regional footprint. The company has further enhanced its clinical capabilities by deploying its advanced iMARS robotic surgery system across three hospitals, enabling minimally invasive procedures that deliver improved accuracy, reduced discomfort, quicker recovery, and better patient outcomes. Alongside robotic surgery, it offers a broad range of complex interventions, including angioplasty, non-surgical valve replacements, leadless pacemakers, bariatric surgery, stroke care, and kidney transplants, strengthening both clinical depth and efficiency. Overall, the company derives its revenue from a broad portfolio of specialties, enabling sustained business growth while mitigating concentration risks across its operations. As of September 30, 2025, it offered more than 30 super-specialty and specialty services across its hospital network.

Valuation of Park Medi World Ltd IPO

Park Medi World Limited is the second-largest private hospital chain in North India with a capacity of 3,000 beds, and the largest operator in Haryana with 1,600 beds as of March 31, 2025. The company operates 14 NABH-accredited multispecialty hospitals, offering 30+ specialties, including neurology, urology, gastroenterology, orthopedics, general surgery, and oncology. Its network is supported by a substantial clinical workforce of 1,014 doctors and 2,142 nurses as of September 30, 2025. The company’s business model focuses on affordable, high-quality healthcare delivery in fast-growing Tier-II North Indian markets, giving it a strong regional scale advantage. The company is positioned to leverage the structural expansion of healthcare demand in North India. Park Medi has built its footprint through a combination of organic expansion and targeted acquisitions, as seen in its diversified subsidiary network across Haryana, Delhi, Punjab, and Rajasthan. The group continues to invest heavily in physical infrastructure; this capex-led strategy supports bed additions, new specialties, and capacity upgrades. India’s healthcare delivery sector continues to benefit from strong macro tailwinds. North India, in particular, remains underpenetrated in hospital beds relative to national averages, creating a long runway for private operators.  On the financial front, the company has demonstrated Revenue CAGR growth of 5.4% between FY23 and FY25, led by the rapid expansion of its hospital network, both organically and through the acquisition of multiple operating subsidiaries across Haryana, Delhi NCR, Punjab, and Rajasthan. Overall, the company’s growth outlook is underpinned by network expansion via brownfield and greenfield projects, deeper penetration of high-margin specialties, and operating leverage from maturing hospitals. At the upper end of the price band at Rs. 162, the company is valued at a P/E multiple of 29.2x FY25 earnings. We, thus, recommend a “SUBSCRIBE” rating for this issue.

What is the Park Medi World Ltd IPO?

The initial public offer (IPO) of Park Medi World Ltd offers an early investment opportunity in Park Medi World Ltd . A stock market investor can buy Park Medi World Ltd IPO shares by applying in IPO before All Park Medi World Ltd shares get listed at the stock exchanges. An investor could invest in Park Medi World Ltd IPO for short term listing gain or a long term.

To apply for the Park Medi World Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Park Medi World Ltd IPO is opening on 10th Dec 2025.  Apply Now

The Lot Size of Park Medi World Ltd IPO is 92 equity shares. Login to your account now.

The allotment Date for Park Medi World Ltd IPO is 15th Dec 2025.  Login to your account now.

The listing Date for Park Medi World Ltd IPO is 17th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,904. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,93,752. Login to your account now

  • The company’s substantial revenue is derived from women’s healthcare, cardiovascular-diabetes, and pain management, accounting for 65.1% of Q1FY26 revenue. Any underperformance of products in these segments, or increased competition, could materially impact the company’s revenue, profitability, and cash flows.
  • The company’s 27 engine brands contribute 72.34% of domestic sales (MAT Jun’ 25), with significant reliance on key brands such as B-29 and Myoril. Any adverse developments impacting the performance, market acceptance or competitive positioning of these core brands could materially affect the company’s business, financial performance and cash flows.
  • The company’s domestic sales exhibit a high regional concentration, with Gujarat, Maharashtra, Chhattisgarh, Goa, and Madhya Pradesh collectively accounting for 47.30% of MAT Jun ’25 revenues. This concentration heightens exposure to region-specific disruptions, including regulatory actions, competitive intensification, supply-chain constraints, which could materially affect sales traction in these key markets and, in turn, weigh on the overall business performance, financial outcomes and cash flow stability.

The Park Medi World Ltd IPO be credited to the account on allotment date which is 15th Dec 2025. Login to your account now 

The prospectus of Park Medi World Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Corona Remedies Ltd IPO : Subscribe

  • Date

    08th Dec 2025 - 10th Dec 2025

  • Price Range

    Rs.1008 to Rs 1062

  • Minimum Order Quantity

    14

Price Lot Size Issue Date Issue Size
₹1008 to ₹1062 14 08th Dec, 2025 –10th Dec, 2025 ₹655.37 Cr

Corona Remedies Ltd

Corona Remedies Ltd. is an India-focused branded formulations player with a strong presence in women’s healthcare, cardio-diabetes, pain management, urology and other multispecialty therapies. Backed by a diversified portfolio of 71 brands and a proven brand-building capability, it has emerged as one of the fastest-growing companies in the Indian Pharmaceutical Market (IPM). As per CRISIL, it recorded the fastest growth among the top 30 IPM companies during MAT Jun’24-Jun’25, delivering a domestic sales CAGR of 13.6% vs. IPM’s 7.9%, and was the second fastest-growing over MAT Jun’22-Jun’25 with a CAGR of 16.8% vs. IPM’s 9.2%. Growth has been supported by substantial volume expansion (5.7%) and an above-market contribution from new launches (4.6%). The company’s business is anchored by 27 “engine brands”, contributing over 72% of domestic sales (MAT Jun’25), including leadership brands such as Myoril, Cor, Trazer, Cor-9 and B-29. Several top brands hold #1-to #5 rankings in their respective IPM subgroups, underscoring substantial franchise equity. Chronic and sub-chronic therapies are gaining share, rising from 63.8% (MAT Jun’22) to 70.1% (MAT Jun’25), and this segment is delivering a robust 20.5% CAGR, more than twice the IPM growth rate. The company’s differentiated commercial strategy, focusing on the middle of the pyramid and specialist doctors, has significantly strengthened its prescription base. Specialists/super-specialists account for ~76% of prescriptions (vs. IPM’s 61%), driving an improvement in market rank from #37 (MAT Jun’22) to #29 (MAT Jun’25). It is currently the 17th largest in its covered markets and holds strong positions across key therapies: #6 in women’s health, #22 in cardiology-diabetes, #5 in pain management, and #9 in urology. A pan-India field force of 2,671 medical representatives across 22 states ensures deep market penetration. The company continues to enhance manufacturing capabilities through two formulation plants (Gujarat and Himachal Pradesh) with an installed capacity of 1.29 billion units. It is commissioning a hormone formulation facility (expected in FY27). R&D strength is supported by two DSIR-recognized centres with over 100 personnel, focusing on formulation development, process optimization and product lifecycle management.

Objective of the Corona Remedies Ltd IPO

The net proceeds from the fresh issue will be used towards the following purposes:

  • The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders after deduction of offer related expenses and relevant taxes thereon to be borne by the respective selling shareholders.;
  • General corporate purposes. 

Rationale To Corona Remedies Ltd IPO

Second fastest-growing among top 30 pharma players, ready to ride India’s growth wave

The company is one of the fastest-growing players in the Indian pharmaceutical market, ranking second in growth among the top 30 domestic pharma companies between MAT June 2022 and MAT June 2025. Its strong 16.8% domestic sales CAGR, which significantly outpaces IPM’s 9.2% growth, reflects superior execution across key therapeutic areas, including women’s health, cardiology, pain management, and urology. A differentiated portfolio strategy, focused on high-growth chronic and speciality segments, has driven meaningful scale-up in brand leadership, with the company achieving the largest rank improvement among the top 30 IPM players during the period. The company also leads in new product momentum, with a 14.4% share of launches above Rs. 50 mn higher than the top-30 peer set and the broader IPM, supported by a substantial 60% share of products in the growth stage of the lifecycle. With the domestic formulations market expected to grow at an 8-9% CAGR through FY30, led by rising chronic disease burden and increasing demand for gynaecology, cardiovascular-diabetes, and urology therapies, the company is well-positioned to benefit disproportionately from these structural tailwinds. Its focused presence in high-growth segments, brand-centric commercial model and strong pipeline collectively provide a robust platform for sustained outperformance in the Indian pharmaceutical market.

Diversified portfolio with engine brands to accelerate growth

The company offers a highly diversified and fast-growing branded formulations portfolio across women’s healthcare, cardio-diabeto, pain management and urology, with these four targeted therapy areas as contributing ~67-68% of domestic sales and delivering a strong 22-24% CAGR over MAT FY22-FY25, significantly outperforming the IPM. Leadership positions across key brands reinforce its competitive strength: Myoril, COR and Trazer ranked #1; COR-9, Alkashot and Stimucor ranked #3; Argihope and Evtab ranked #4; and B-29, C-HOP and Bisobis ranked #5 in their respective sub-groups. The strategic acquisition of Myoril has further accelerated growth, driving ~52-90% revenue expansion, strengthening the pain management portfolio. A strong brand-building track record underpins the company’s performance, with 27 “engine” brands, contributing ~72% of revenues and growing at an impressive 20.7% CAGR. Twelve of these engine brands rank among the top five in their categories, demonstrating deep franchise equity and robust marketing capabilities. At the same time, a rising share of chronic and sub-chronic therapies from 63.8% to 70.1% over three years enhances revenue visibility, stability and profitability, with this segment growing at 20.5% CAGR, more than double the broader IPM. Overall, the company’s strong leadership across key therapy clusters, brand-driven growth engine, expanding presence in chronic/sub-chronic therapies, and acquisitions and in-licensing partnerships collectively position it for sustained growth.

Valuation of Corona Remedies Ltd IPO

Corona Remedies Limited is an India-focused branded formulations company with a significant presence in women’s healthcare, cardiovascular diabetology, pain management, urology, and related therapies. Corona Remedies ranks as the second fastest-growing pharma company among India’s top 30 by domestic sales, delivering a strong 22-24% CAGR over MAT FY22-FY25, significantly outperforming the IPM.  With the Indian domestic formulations market expected to grow at 8-9% CAGR through FY2030, led by higher chronic disease prevalence, rising healthcare access, and strong growth in gynecology, cardio-diabetes and urology therapies, the company stands to benefit disproportionately given its high exposure to these faster-growing segments. Corona Remedies is well-positioned to leverage this growth, demonstrated by its strong domestic franchise and a healthy growth in the broader Indian market. The company offers an opportunity to invest in a growth-oriented, domestic-branded pharma with a robust presence across core therapies and exposure to secular growth trends in the Indian market. On the financial front, the company has demonstrated CAGR growth of 16%/37%/33% in Revenue/EBITDA/PAT between FY23 and FY25, led by continued momentum in chronic/sub-chronic therapies, ramp-up of recent acquisitions such as Myoril, and differentiated in-licensing partnerships, further strengthening long-term earnings potential. Overall, the company’s strong growth profile, leadership in high-value therapies, and alignment with sector tailwinds support a positive long-term outlook, positioning it well to capture above-industry growth. At the upper end of the price band at Rs. 1,062, the company is valued at a P/E multiple of 43.5x FY25 earnings. We, thus, recommend a “SUBSCRIBE” rating for this issue.

What is the Corona Remedies Ltd IPO?

The initial public offer (IPO) of Corona Remedies Ltd offers an early investment opportunity in Corona Remedies Ltd . A stock market investor can buy Corona Remedies Ltd IPO shares by applying in IPO before All Corona Remedies Ltd shares get listed at the stock exchanges. An investor could invest in Corona Remedies Ltd IPO for short term listing gain or a long term.

To apply for the Wakefit Innovations Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Corona Remedies Ltd IPO is opening on 08th Dec 2025.  Apply Now

The Lot Size of Corona Remedies Ltd IPO is 14 equity shares. Login to your account now.

The allotment Date for Corona Remedies Ltd IPO is 11th Dec 2025.  Login to your account now.

The listing Date for Corona Remedies Ltd IPO is 15th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,868. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,93,284. Login to your account now

  • The company’s substantial revenue is derived from women’s healthcare, cardiovascular-diabetes, and pain management, accounting for 65.1% of Q1FY26 revenue. Any underperformance of products in these segments, or increased competition, could materially impact the company’s revenue, profitability, and cash flows.
  • The company’s 27 engine brands contribute 72.34% of domestic sales (MAT Jun’ 25), with significant reliance on key brands such as B-29 and Myoril. Any adverse developments impacting the performance, market acceptance or competitive positioning of these core brands could materially affect the company’s business, financial performance and cash flows.
  • The company’s domestic sales exhibit a high regional concentration, with Gujarat, Maharashtra, Chhattisgarh, Goa, and Madhya Pradesh collectively accounting for 47.30% of MAT Jun ’25 revenues. This concentration heightens exposure to region-specific disruptions, including regulatory actions, competitive intensification, supply-chain constraints, which could materially affect sales traction in these key markets and, in turn, weigh on the overall business performance, financial outcomes and cash flow stability.

The Corona Remedies Ltd IPO be credited to the account on allotment date which is 12th Dec 2025. Login to your account now 

The prospectus of Corona Remedies Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Wakefit Innovations Ltd IPO : Subscribe

  • Date

    08th Dec 2025 - 10th Dec 2025

  • Price Range

    Rs.185 to Rs 195

  • Minimum Order Quantity

    76

Price Lot Size Issue Date Issue Size
₹185 to ₹195 76 08th Dec, 2025 –10th Dec, 2025 ₹1,288.89 Cr

Wakefit Innovations Ltd

WakeFit Innovations Ltd. is the largest D2C home and furnishings brand in India by revenue in FY24. Within just nine years of operations, it has emerged as the fastest homegrown player among organized peers to surpass total income of Rs. 1000 crores in the home and furnishings market, with Rs. 986 crores generated from operations as of March 31, 2024. Revenue from operations has grown at a robust CAGR of 24.9% between FY22 and FY24, approximately 1.6x the average growth rate of organized competitors, highlighting strong brand momentum, customer adoption, and market share gains. The company operates an extensive omnichannel model, offering a comprehensive portfolio spanning mattresses, furniture, and furnishings, ensuring consistent consumer engagement across digital and offline formats. Its full-stack, vertically integrated operating structure covering product conceptualization, design, engineering, manufacturing, distribution, and customer experience, provides end-to-end control, enabling superior product quality, operational efficiencies, and faster innovation cycles. Wakefit’s business model is anchored in full-stack control from design to manufacturing and last-mile delivery. Its infrastructure backbone comprises 1 Mother Warehouse, 7 Inventory Holding Points (INHPs) and 18 Points of Delivery (PODs), supported by an owned fleet and trained installers. This deep operational moat, difficult for competitors to replicate, enables scalable production, predictable installation, and efficient inventory management. Wakefit further strengthens its reach through 125+ COCO stores and an omnichannel presence, while its mattress-led flywheel lowers customer acquisition cost. The company operates across three segments, mattresses 60%, furniture 30% and furnishings 10%.

Objective of the Wakefit Innovations Ltd IPO

The company will utilize net proceeds in the following manner:

  • Capital expenditure to be incurred by the company for setting up of 117 new COCO – Regular Stores;
  • Expenditure for lease, sub-lease rent and license fee payments for existing COCO – Regular Stores;
  • Capital expenditure to be incurred by the company for purchase of new equipment and machinery;
  • Marketing and advertisement expenses towards enhancing the awareness and visibility of the brand; and
  • General corporate purposes.

Rationale To Wakefit Innovations Ltd IPO

Largest and fastest growing D2C home and furnishing solutions destination

The company operates as a scaled home and furnishing solutions provider with a comprehensive product portfolio spanning mattresses, furniture, and furnishings, supported by a strong omnichannel presence. It is the largest D2C home and furnishings brand in India by revenue in FY24 and the fastest homegrown player among organized peers to surpass Rs. 1000 crores in total income within just nine years of operations (Rs. 986 crores revenue from operations). Revenue from operations grew at a robust 24.9% CAGR over FY22-FY24, approximately 1.6x the average growth of organized industry players, highlighting strong execution and brand momentum. The company’s differentiated strategy is anchored in a high share of direct-to-consumer sales. Own channels (website + COCO stores) contributed 65%, 57%, 58% and 57% of revenue in H1FY26, FY25, FY24 and FY23, respectively, demonstrating the brand’s ability to attract and convert customers within proprietary platforms. The D2C-heavy mix enhances customer engagement, drives higher order values, boosts repeat purchases, and optimizes conversion rates through data-driven insights and direct customer feedback. Importantly, direct channels also deliver superior profitability by bypassing third-party marketplace commissions and distributor margins. The company has aggressively scaled its COCO network from 23 stores in FY23 to 125 stores across 62 cities by September 2025, strengthening experiential retail, increasing touchpoints, and reinforcing brand visibility. These stores, combined with the capital-efficient and scalable website channel, create an integrated ecosystem that allows the company to control pricing, experience, product education, and customer lifetime value. A majority of the company’s revenue originates from its own channels, underscoring the brand’s consumer trust and preference over established marketplaces. The direct interface with customers enables richer insights for product innovation, personalized marketing, and targeted retention interventions, further strengthening the brand’s competitive moat and supporting continued growth.

Full-stack vertically integrated operations with differentiated processes and technical capabilities

The company has built strong in-house design, engineering, and manufacturing capabilities, anchored in a technology-centric R&D framework. Advanced CAD/CAM systems enable precision design, rapid prototyping, and digitally integrated manufacturing. Designs are stored and updated through a cloud-based architecture, allowing real-time synchronization with machinery across facilities. This end-to-end digital workflow materially reduces manual intervention, minimizes reconfiguration downtime, improves consistency, and enhances overall production efficiency. The company’s focus on ergonomics, functionality, and dimensional accuracy supports differentiated product quality and faster design-to-market cycles. On the operations front, the company has established a scalable and cost-efficient supply chain infrastructure comprising a 1.55-lakh sq. ft. mother warehouse in Hosur, seven INHPs, and 18 PODs as of September 2025. The mother warehouse functions as the central inventory and dispatch hub, while INHPs hold key SKUs, particularly mattresses and marketplace-driven categories to compress delivery timelines and reduce logistics costs. PODs serve as hyperlocal transit hubs supporting last-mile delivery and on-ground installation. This distributed logistics architecture enhances fulfillment speed and customer experience, particularly in larger-format categories like furniture. Additionally, a dedicated workforce of 198 installation specialists ensures professional assembly and post-sales service, reinforcing customer satisfaction and strengthening the company’s brand promise.

Valuation of Wakefit Innovations Ltd IPO

Wakefit’s business model is anchored in full-stack control from design to manufacturing and last-mile delivery. Its infrastructure backbone comprises 1 Mother Warehouse, 7 Inventory Holding Points (INHPs) and 18 Points of Delivery (PODs), supported by an owned fleet and trained installers. This deep operational moat, difficult for competitors to replicate, enables scalable production, predictable installation, and efficient inventory management. Wakefit further strengthens its reach through 125+ COCO stores and an omnichannel presence, while its mattress-led flywheel lowers customer acquisition cost. The company operates across three segments, mattresses 60%, furniture 30% and furnishings 10%. India’s Home & Furnishings market is estimated to be Rs. 2.8 to 3.0 trillion (USD 34 to 36 billion) as of CY24, and is projected to grow to reach Rs. 5.2 to 5.9 trillion (USD 63 to 71 billion) by CY30. The home and furnishings market is projected to grow at 11% to 13% CAGR from CY24 to CY30, fueled by organized retail growth, rising online dominance, and premiumization. This provides substantial headroom for Wakefit Innovations Ltd. to accelerate its scale-up. The company is currently prioritizing structural cost optimization by streamlining its supply chain, shifting from a factory to mother warehouse model to direct dispatches to INHPs, which is expected to improve efficiencies and reduce logistics costs. On the financial front, revenue grew at a robust CAGR of 25.2% between FY23 and FY25, losses narrowed in FY24, and the company delivered a profit of Rs. 36 crores in FY25. At the upper price band of Rs. 195, WakeFit Innovations Ltd. is valued at a P/S multiple of 5.5x based on FY25 sales. Given the company’s expansion plans, expanding margins, scalable business model, and industry growth potential, we believe the valuation is justified. Thus, we recommend a “SUBSCRIBE” rating for this issue with a medium to long-term investment horizon.

What is the Wakefit Innovations Ltd IPO?

The initial public offer (IPO) of Wakefit Innovations Ltd offers an early investment opportunity in Wakefit Innovations Ltd . A stock market investor can buy Wakefit Innovations Ltd IPO shares by applying in IPO before All Wakefit Innovations Ltd shares get listed at the stock exchanges. An investor could invest in Wakefit Innovations Ltd IPO for short term listing gain or a long term.

To apply for the Wakefit Innovations Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Wakefit Innovations Ltd IPO is opening on 08th Dec 2025.  Apply Now

The Lot Size of Wakefit Innovations Ltd IPO is 76 equity shares. Login to your account now.

The allotment Date for Wakefit Innovations Ltd IPO is 11th Dec 2025.  Login to your account now.

The listing Date for Wakefit Innovations Ltd IPO is 15th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,820. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,92,660. Login to your account now

  • The company’s performance is closely tied to the strength of its flagship “Wakefit” brand, which anchors its mattress, furniture, and furnishings portfolio. Given the brand’s central role in driving customer acquisition, pricing power, and category expansion, any dilution, impairment, or negative perception of the Wakefit brand could materially impact business momentum, operating performance, financial stability, and cash flows. Maintaining brand integrity is therefore a critical strategic and operational priority for the company.
  • The company derives a significant portion of its revenue from the mattress product category.  Revenue from the sale of mattresses accounted for 60.65%, 61.35%, 57.54% and 63.50% of revenue from operations in the six-month period ended September 30, 2025 and FY25, FY24 and FY23, respectively. Any shifts in consumer preferences, any disruption in the supply chain, could adversely affect business, results of operations, financial condition and cash flows.

The Wakefit Innovations Ltd IPO be credited to the account on allotment date which is 12th Dec 2025. Login to your account now 

The prospectus of Wakefit Innovations Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Vidya Wires Ltd IPO : Subscribe

  • Date

    03rd Dec 2025 - 05th Dec 2025

  • Price Range

    Rs.48 to Rs 52

  • Minimum Order Quantity

    288

Price Lot Size Issue Date Issue Size
₹48 to ₹52 288 03rd Dec, 2025 –05th Dec, 2025 ₹300.01 Cr

Vidya Wires Ltd

Based out of Gujarat, Vidya Wires Ltd. (VWL) is involved in the manufacturing of insulated copper and aluminum wires that are used across wide range of industries like energy generation & transmission, electrical systems, electric motors, clean energy systems, electric mobility, and railways. Their product portfolio includes precision-engineered Enameled Wires, Enameled Copper Rectangular Strips, Paper Insulated Copper Conductors, Copper Busbar and Bare Copper Conductors, Specialized Winding Wires, PV Ribbon and Aluminum Paper Covered Strips, among others. With an annual capacity of 19,680 MT, the company ranks as the fourth largest manufacturer in the industry, with a market share of 5.7% of installed capacity in FY25. Their manufacturing facilities are strategically located near the ports of Hazira and Mundra, providing a logistical advantage for exports. VWL is a pre-approved supplier to Power Grid Corporation of India Ltd. and also holds UL approval, enabling it to export enameled copper and aluminum wire to the US. In Q1FY26, revenue comprised 88% domestic sales, 11% exports, with the remainder coming from other operations, hinting towards more focus on the domestic market as also outlined by the management. The company offers a diverse portfolio of winding and conductivity products across 12 product categories with over 8,000 SKUs, with sizes ranging from as thin as 0.07 mm to as thick as 25 mm. With its wide product range, the company is able to serve customers across 19 Indian states and union territories, with Gujarat and Maharashtra contributing 69% of revenue in Q1FY26. With focus on the environment, the company has fulfilled 25% of power requirements from renewable sources like solar and windmills in Q1FY26.

Objective of the Vidya Wires Ltd IPO

The company proposes to utilize net proceeds from the issue towards the following objects:

  1. Funding capital expenditure requirements for setting up new project in its subsidiary viz. ALCU ;
  2. Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the company; and
  3. General corporate purposes.

Rationale To Vidya Wires Ltd IPO

Capacity expansion and increased product offering to significantly enhance market share

With an existing installed capacity of 19,680 MT per annum, the company intends to deploy IPO proceeds towards an additional 18,000 MT per annum, raising cumulative capacity to 37,680 MT. The expansion is scheduled for commissioning by Q3FY26, positioning the company as India’s third-largest manufacturer by installed capacity. Currently, the company has 12 product categories with over 8,000 SKU and intends to introduce 6 additional categories through this expansion, targeting evolving demand and improved customer stickiness. The company intends to add new products like copper foils, copper components, continuously transposed copper conductors, PV round ribbon, solar cables, multi paper covered copper conductors, enameled aluminium winding wires, and enameled aluminium rectangular strips to its current product portfolio. This strategic expansion comes after existing two units reach near optimum capacity utilisation. In Q1FY26, Unit 1 operated at a utilization rate of 80%, up from 57% in FY23, while Unit 2 operates at 97%, up from 72% in FY23. This is a testament to the rising demand as India’s copper and aluminium wiring industry is set for steady growth, driven by electric vehicle adoption, renewable energy investments, and large-scale infrastructure projects. The sector is projected to grow steadily, with products such as enamelled copper winding wire, paper-covered aluminium conductors, PV ribbons, and solar PVC cables fuelling sales. Transformers are one of the key end-use industries driving growth in the copper sector. With rising power demand and the rapid adoption of renewable energy, India requires a stronger and wider power grid for distribution and as this ecosystem is heavily dependent on copper, it provides a strong tailwind that is expected to drive growth. According to the management guidance, this capacity expansion and increased product offering is expected to double VWL’s market share from 5.7% to 11.3%.

De-risked business with diversified supplier and customer base along with in-built hedging mechanism shielding margins

Over FY2023-25 period, the company served over 318 customers, including over 19 international customers in more than 18 countries across 5 continents including the US, Saudi Arabia, UAE, Australia, Canada, Egypt, Singapore, etc. with none of its customer singly contributing over 9% of annual revenues. VWL serves broad industry base, with power & transmission contributing 49%, electrical 22%, renewable EV & automotive 11%, general engineering 10%, and consumer durables 8% in Q1FY26. While the mix has remained stable over the past three years, renewables have shown a notable increase from 7% in FY23 to 11% in Q1FY26. Going forward, the company expects a higher revenue share from this segment, as aluminium product sales in renewables and EVs are expected to drive margin improvement. Over the years, VWL has developed relationships with its customers including Adani Wilmar, Transformers & Rectifiers (India), Schneider Electric Infrastructure, etc., which have shown high stickiness as evident by 80% of business coming from repeat customers. On the supply side, out of total requirement of copper rods, about 35%-40% was manufactured in-house from copper cathodes and the remaining was purchased from external suppliers evenly split between Vedanta Ltd., Marubeni Corporation and Union Copper rod. The raw material requirement is balanced, with a 50:50 split between domestic and imported supplies, thereby reducing supply chain risks. To mitigate the risk of copper price volatility, the company employs a no-cost hedging mechanism wherein raw material supply is booked only after customer orders are confirmed at prices quoted on the London Metal Exchange, thereby shielding margins. 

Valuation of Vidya Wires Ltd IPO

Vidya Wires Ltd. (VWL), based out of Gujarat, manufactures insulated copper and aluminum wires used across industries such as energy, electrical systems, clean energy, EVs, and railways. With an annual capacity of 19,680 MT and planned expansion to 37,680 MT (+18,000 MT), ranking it the third largest manufacturer in the industry. It currently holds a 5.7% market share which is expected to double to 11.3%, driven by capacity expansion and addition of six new product categories serving customers across 19 states, with Gujarat and Maharashtra contributing 69% of Q1FY26 revenue. Manufacturing facilities near Hazira and Mundra ports provide export advantages to the company. On the financial front, the company delivered a revenue growth of 21% over FY2023-25 period to reach Rs. 1,486 crores. For FY25, the EBITDA margin of peers ranged between 3% and 5%, while VWL showed a steady growth increasing from 3.5% in FY23 to 4.3% in FY25. The margins are expected to improve, with the increase in revenue contribution from high margin business of EV and renewables. The company delivered a robust PAT growth of 38% CAGR over FY2023-25 period. Return ratios remained healthy, with RoE at 25% (peer average 15%) and RoCE at 20% (peer average 21%) in FY25. Historically, the company maintained a consistent debt to equity ratio around 0.9x, with fixed asset turnover reaching a high of 36x in FY25. At the upper end of the price band of Rs. 52 per share, the issue is valued at a P/E of 27.1x based on FY25 earnings, which appears highly lucrative given the industry average is 37x. Given strong growth prospects and planned expansion, we recommend a “SUBSCRIBE” rating for this issue.

What is the Vidya Wires Ltd IPO?

The initial public offer (IPO) of Vidya Wires Ltd offers an early investment opportunity in Vidya Wires Ltd . A stock market investor can buy Vidya Wires Ltd IPO shares by applying in IPO before All Vidya Wires Ltd shares get listed at the stock exchanges. An investor could invest in Vidya Wires Ltd IPO for short term listing gain or a long term.

To apply for the Vidya Wires Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Vidya Wires Ltd IPO is opening on 03rd Dec 2025.  Apply Now

The Lot Size of Vidya Wires Ltd IPO is 288 equity shares. Login to your account now.

The allotment Date for Aequs Ltd IPO is 08th Dec 2025.  Login to your account now.

The listing Date for Vidya Wires Ltd IPO is 10th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,976. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,94,688. Login to your account now

  • Execution Risk: Timely commissioning of the planned 18,000 MT capacity expansion by Q3FY26 is critical; any delays or cost overruns could impact growth and market share targets.
  • Industry Dependence: Heavy reliance on copper and aluminum wiring demand from EVs, renewables, and infrastructure projects means any slowdown in these sectors could affect revenue growth and margins.

The Aequs Ltd IPO be credited to the account on allotment date which is 09th Dec 2025. Login to your account now 

The prospectus of Vidya Wires Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Aequs Ltd IPO : Subscribe

  • Date

    03rd Dec 2025 - 05th Dec 2025

  • Price Range

    Rs.118 to Rs 124

  • Minimum Order Quantity

    120

Price Lot Size Issue Date Issue Size
₹118 to ₹124 120 03rd Dec, 2025 –05th Dec, 2025 ₹921.81 Cr

Aequs Ltd

Aequs Limited is a precision manufacturing company with differentiated engineering capabilities and is the only precision component manufacturer in India to offer fully vertically integrated aerospace manufacturing within a single SEZ. The company is among the few in the country with niche metallurgy expertise, including precision machining of titanium and other high-end alloys for global aerospace clients. Aequs operates three vertically integrated ecosystems in India, comprising the company, its suppliers, and joint ventures, enabling end-to-end manufacturing aligned with customer specifications. It has also expanded globally through strategic acquisitions in North America (2015) and France (2016), strengthening its capabilities and broadening its aerospace product portfolio. As of FY25, Aequs had one of the largest aerospace component portfolios in India, spanning engine systems, landing systems, cargo and interiors, structures, assemblies, and turning operations, and by H1FY26, it had delivered over 5,000 products across major commercial aircraft programs such as the A220, A320, B737, A330, A350, B777, and B787. The company maintains long-standing relationships with marquee aerospace OEMs, including Airbus, Boeing, Bombardier, Collins Aerospace, Spirit AeroSystems, Safran, GKN Aerospace, Mubea Aerostructures, Honeywell, Eaton, and Sabca, while also serving leading consumer brands such as Hasbro, Spinmaster, Wonderchef, and Tramontina through its growing consumer segment, which includes cookware, small appliances, outdoor toys, figurines, and components for portable electronics. In FY25, Aequs derived 89.2% of its revenue from Aerospace and 10.8% from the consumer segment, with EBITDA margins of 19.4% and -28.7% respectively; in H1FY26, Aerospace contributed 88.2% and consumer segment has 11.8% share, with margins improving to 24.7% and -23.9%, underscoring strong operating leverage in aerospace and ongoing scale-up investments in the consumer business.

Objective of the Aequs Ltd IPO

Out of the total issue size of Rs. 922 crores, Rs. 252 crores comprises OFS. The company proposes to utilize net proceeds (Rs. 670 crores) from the issue towards the following objects:

  • Repayment and/ or prepayment, in full or in part, of certain outstanding borrowings and prepayment penalties, as applicable, availed by the company and three of its wholly owned subsidiaries;
  • Funding capital expenditure to be incurred on account of the purchase of machinery and equipment by the company and one of its wholly-owned subsidiaries;
  • Funding inorganic growth through unidentified acquisitions, other strategic initiatives and general corporate purposes.

Rationale To Aequs Ltd IPO

Integrated manufacturing platform enhances scalability, cost efficiency, and customer stickiness

Aequs’ integrated aerospace manufacturing platform provides a structural advantage that directly supports long-term scalability, operational efficiency, and customer retention. By consolidating end-to-end capabilities such as machining, forging, surface treatment, metal forming, and assembly within a single SEZ ecosystem, the company eliminates multi-vendor coordination challenges, shortens production cycles, and achieves tighter control over quality and costs. This integrated setup, supported by over 2.9 million machining/molding hours and a large base of CNC and molding machines, allows Aequs to manufacture complex, high-precision components at scale and respond quickly to customer ramp-up requirements. The ecosystem structure strengthens operational resilience, enables seamless onboarding of new programs, and enhances the company’s ability to deliver consistent turnaround times, which is a critical differentiator for global OEMs. As aerospace OEMs increasingly shift towards suppliers with consolidated capabilities, Aequs’ integrated model positions it to capture higher wallet share, participate in more sophisticated work packages, and improve margin visibility over the medium term.

Deep OEM relationships strengthen revenue visibility and reinforce high entry barriers

Aequs’ deep and long-standing relationships with marquee global OEMs (the top three customer groups had an average tenure of 15 years with Aequs) provide a high degree of business visibility and create durable competitive moats in an industry characterised by stringent qualification cycles and high switching costs. Aerospace OEMs typically undertake multi-year validation, testing, and first-article inspection processes before awarding production mandates, making supplier onboarding both expensive and time-consuming. Aequs’ sustained performance across quality, delivery, and technical capability has enabled it to build strong partnerships with customers such as Airbus, Boeing, Safran, Collins Aerospace, and Spirit AeroSystems, many of whom have expanded their engagement over the years. These relationships not only anchor recurring revenue streams but also enhance the company’s ability to win incremental, higher-value work packages as OEMs consolidate their supplier bases in favor of integrated, reliable partners. The company’s track record, reinforced by industry recognitions such as the Airbus Ramp-up Champion Award, further strengthens its positioning as a .

Valuation of Aequs Ltd IPO

Aequs Limited is a capability-led precision manufacturing company with a strong presence in the global aerospace supply chain and a growing footprint in high-precision consumer categories, supported by three integrated manufacturing ecosystems in India and complementary facilities in North America and Europe. The company’s ability to execute complex machining, forging, surface treatment, and assembly work within a consolidated SEZ platform provides meaningful advantages in cost efficiency, turnaround time, and scalability. This operational depth, combined with long-standing relationships with marquee aerospace OEMs and differentiated technical capabilities built through strategic acquisitions and joint ventures, positions Aequs as a trusted supplier in programs with high entry barriers and multi-year visibility. These strengths are reinforced by favourable industry tailwinds, including a sustained commercial aerospace production upcycle, increased global outsourcing to cost-competitive manufacturing hubs like India, supply-chain diversification away from single-country dependence, and supportive domestic policies. On the financial front, the company has demonstrated CAGR growth of 7%/46%/-2.9% in Revenue/EBITDA/PAT between FY23 and FY25. Given its strong positioning within the global aerospace supply chain, reinforced by high entry barriers, long-standing OEM relationships and a differentiated, integrated manufacturing model, we believe Aequs is well placed to benefit from the ongoing commercial aerospace upcycle and the structural shift toward outsourcing to cost-competitive, capability-rich suppliers. While the consumer segment remains in a build-out phase, its long-term potential, combined with the robust and a predictable aerospace business, provides a balanced growth runway. In light of these strengths, we recommend a “SUBSCRIBE” rating for this issue.

What is the Aequs Ltd IPO?

The initial public offer (IPO) of Aequs Ltd offers an early investment opportunity in Aequs Ltd . A stock market investor can buy Aequs Ltd IPO shares by applying in IPO before All Aequs Ltd shares get listed at the stock exchanges. An investor could invest in Aequs Ltd IPO for short term listing gain or a long term.

To apply for the Aequs Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Aequs Ltd IPO is opening on 03rd Dec 2025.  Apply Now

The Lot Size of Aequs Ltd IPO is 120 equity shares. Login to your account now.

The allotment Date for Aequs Ltd IPO is 08th Dec 2025.  Login to your account now.

The listing Date for Aequs Ltd IPO is 10th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,880. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,93,440. Login to your account now

  • The company is highly dependent on ten of its largest customer groups, which account for a significant portion of its revenue from operations (82.5% in H1FY26 and 88.6% in FY25). Any failure to maintain its relationships with these customer groups, or any adverse changes affecting their financial condition, will adversely affect the company’s business.
  • The company derives a substantial portion of its revenue from the Aerospace Segment (88.23% in H1FY26 and 89.19% in FY25). Any decline in demand for aerospace products or adverse developments affecting the economics of this segment could materially impact the company’s business.
  • All of the company’s manufacturing units in India are concentrated in Karnataka, exposing it to regional risks that could adversely impact its operations.

The Aequs Ltd IPO be credited to the account on allotment date which is 09th Dec 2025. Login to your account now 

The prospectus of Meesho Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Meesho Ltd IPO : Subscribe

  • Date

    03rd Dec 2025 - 05th Dec 2025

  • Price Range

    Rs.105 to Rs 111

  • Minimum Order Quantity

    135

Price Lot Size Issue Date Issue Size
₹105 to ₹111 135 03rd Dec, 2025 –05th Dec, 2025 ₹5421.20 Cr

Meesho Ltd

Meesho Ltd., incorporated in 2015, operates a multi-sided technology platform that drives e-commerce in India by bringing together four key stakeholders – consumers, sellers, logistics partners, and content creators. Its e-commerce marketplace, branded as Meesho, has become the largest in India in terms of placed orders and annual transacting users during the twelve months ended June 30, 2025. The platform aims to serve consumers across all segments by focusing on affordability, accessibility, and engagement, with an emphasis on offering “Everyday Low Prices.” Meesho’s technology-first operations, platform scale, and operational efficiency enable low-cost order fulfillment for sellers. Coupled with its zero-commission model, this helps reduce overall seller costs and supports a wide assortment of products ranging from low-cost unbranded goods to regional and national brands, at affordable prices. Meesho uses advanced AI/ML algorithms to provide a personalized, discovery-led shopping experience that resembles offline window shopping, making online shopping easier and more engaging. Technology forms the backbone of the platform, ensuring reliable, scalable, and efficient e-commerce transactions at a population scale. The company operates across two segments: Marketplace, which connects consumers, sellers, logistics partners, and content creators; and New Initiatives, which include a low-cost local logistics network for daily essentials and a digital financial services platform. Meesho primarily monetizes through seller services such as order fulfillment, advertising, and data insights, while charging no commission to sellers and no platform fee to consumers. Meesho’s consumer base spans various income segments, typically value-focused and seeking a wide assortment of affordable products, including unbranded goods, regional brands, and national brands. Its logistics ecosystem includes first- and last-mile delivery providers, sorting centers, truck operators, and integrated logistics partners. Orders are fulfilled either through its proprietary and unique technology platform, Valmo, which manages a multi-stage logistics network across multiple logistics partners, or through end-to-end logistics providers. Content creators enhance the shopping experience by posting short-form videos and live streams on Meesho and other social media platforms. The company supports them with tools and data insights to improve the effectiveness of their content. Through these initiatives, Meesho continues to experiment with new opportunities and assesses product-market fit, scalability, and unit economics before scaling them further.

Objective of the Meesho Ltd IPO

The company proposes to utilize the net proceeds towards funding the following objects:

  • Investment for cloud infrastructure in Meesho Technologies Pvt. Ltd., its subsidiary;
  • Payment of salaries of existing and replacement hires for the Machine Learning and AI and technology teams for AI and technology development undertaken by Meesho Technologies Pvt. Ltd., its subsidiary;
  • Investment in Meesho Technologies Pvt. Ltd., its subsidiary, for expenditure towards marketing and brand initiatives; and
  • Funding inorganic growth through acquisitions and other strategic initiatives and general corporate purposes.

Rationale To Meesho Ltd IPO

Self-reinforcing flywheels set the foundation for long-term scalability

Meesho’s platform seamlessly facilitates transactions among its four key stakeholders – consumers, sellers, logistics partners, and content creators. At the core of the platform lies its commerce flywheel. As more consumers shop on Meesho due to its wide product assortment and affordable prices, order volumes increase, encouraging sellers to list more products and price them competitively. Rising order volumes also help logistics partners better utilize their capacity, improve fulfillment density, and lower service prices on a per order basis. As fulfillment costs decline, sellers can offer even more competitive pricing and list lower value products, which in turn attracts additional consumers. In parallel, the company has activated a content commerce flywheel to enhance product discovery and consumer engagement. As content volumes on Meesho increase, product discovery improves, driving higher order volumes and strengthening the core commerce flywheel. Together, these interconnected flywheels create strong network effects, improve platform liquidity, and generate large amounts of data on consumer preferences, pricing trends, seller performance, logistics partner performance, and the attractiveness of content. Leveraging the data generated, Meesho’s technology powers decision-making across the platform, such as hyper-personalized feeds and recommendations for consumers, product and pricing insights for sellers, fulfilment efficiency for logistics partners, and better targeting for content creators. This is further supported by the company’s culture of innovation, agility, and first-principles thinking. Overall, this foundation positions Meesho to deliver a seamless experience for all stakeholders while scaling its business in a capital-efficient manner.

AI-driven, technology-first approach to strengthen platform leadership

Every part of Meesho’s platform is driven by technology, enabling the company to scale, lower costs, and enhance overall efficiency while improving value creation for all stakeholders. Instead of depending on manual interventions, Meesho employs a technology-driven approach to problem-solving. The company has integrated GenAI tools across its engineering stack, helping developers and engineers streamline code generation, improve development velocity, and shorten deployment timelines. GenAI capabilities have also been embedded across functions to enhance scale and productivity. Meesho’s marketing and product teams leverage GenAI tools to create quality, contextual visual and video content, accelerating creative development for performance and brand campaigns. The platform is designed so that every stakeholder interaction is technology-driven, ensuring a seamless, intuitive user experience. Its mobile application is designed to be simple and intuitive, incorporating India-specific nuances. When a user opens the app, real-time AI models analyze multiple signals to generate an infinite feed of hyper-personalized product recommendations tailored to individual preferences. To accurately capture consumer intent, Meesho employs a multi-modal search system that supports text, image, and voice search. Every interaction on the platform generates data that feeds its AI/ML models, enhancing personalization. The company has also built platforms and frameworks that enable smooth transitions between technologies. This modular, granular approach allows Meesho to adopt the most efficient technology for each use case without altering its core codebase. Overall, its purpose-built technology stack supports experimentation, enabling the company to test, refine, and scale new ideas effectively.

Valuation of Meesho Ltd IPO

Meesho is a multi-sided technology platform driving e-commerce in India by connecting consumers, sellers, logistics partners, and content creators. Its value-focused marketplace serves consumers across diverse income segments by offering “Everyday Low Prices”. The platform is built to deliver a personalized, discovery-led shopping experience and generates revenue through services offered to sellers, including order fulfillment, advertising, and data insights. India’s e-commerce market is expected to reach Rs. 15-18 trillion in GMV by FY30, penetrating 12-13% of the overall retail sector. A significant portion of new online shoppers will emerge from Tier-2+ cities, which are projected to contribute 51-52% of the country’s e-commerce market by FY30. Meesho is well-positioned to benefit from this shift by offering an affordable, accessible platform tailored to a broad consumer base, enabling it to tap into this growing market opportunity and increase consumer penetration. The company’s interconnected flywheels enhance platform liquidity and generate large amounts of data on consumer preferences, pricing trends, seller performance, logistics efficiency, and content engagement. Meesho adopts a technology-first approach, allowing it to scale efficiently, lower costs, and increase operational effectiveness. On the financial front, while the company has reported higher losses due to one-off expenses, it has been free cash flow positive for the past two years. Meesho’s continuous investment in technology and ongoing improvements to the user experience strengthen its competitive position within the industry compared to its peers. At the upper price band, the company is valued at a Price/Sales multiple of 5.3x based on its FY25 revenue. Given the strong growth outlook of India’s e-commerce market and Meesho’s strategic initiatives to capture rising consumer demand, we recommend a “SUBSCRIBE” rating for this issue.

What is the Meesho Ltd IPO?

The initial public offer (IPO) of Meesho Ltd offers an early investment opportunity in Meesho Ltd . A stock market investor can buy Meesho Ltd IPO shares by applying in IPO before All Meesho Ltd shares get listed at the stock exchanges. An investor could invest in Meesho Ltd IPO for short term listing gain or a long term.

To apply for the Meesho Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Meesho Ltd IPO is opening on 03rd Dec 2025.  Apply Now

The Lot Size of Meesho Ltd IPO is 135 equity shares. Login to your account now.

The allotment Date for Meesho Ltd IPO is 08th Dec 2025.  Login to your account now.

The listing Date for Meesho Ltd IPO is 10th Dec 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,985. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,94,805. Login to your account now

  • A significant portion of orders on Meesho are paid through cash on delivery (CoD). In the past few years, more than 75% of shipped orders have been on a COD basis. This payment method lowers successful delivery rates and increases operational inefficiencies and risks associated with cash handling.
  • Failure to effectively deal with any misuse of the platform or illegal activities by stakeholders, third-party service providers, or employees could damage the company’s business and reputation and expose the company to liabilities.
  • If sellers on the platform fail to identify and respond to changing consumer preferences and spending patterns in a timely manner, demand for their products may decline, adversely impacting the company’s revenue, cash flows, and results of operations.

The Meesho Ltd IPO be credited to the account on allotment date which is 09th Dec 2025. Login to your account now 

The prospectus of Meesho Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE

Sudeep Pharma Ltd IPO : Subscribe

  • Date

    21st Nov 2025 - 25th Nov 2025

  • Price Range

    Rs.563 to Rs 593

  • Minimum Order Quantity

    25

Price Lot Size Issue Date Issue Size
₹563 to ₹593 25 21st Nov, 2025 –25th Nov, 2025 ₹895.00 Cr

Sudeep Pharma Ltd

Sudeep Pharma is a technology-led manufacturer of excipients and specialty ingredients serving the pharmaceutical, food, and nutrition industries, with a strong focus on advancing the global healthcare ecosystem. Leveraging proprietary technologies across encapsulation, spray drying, granulation, trituration, liposomal preparations, and blending, the company drives innovation in ingredient performance and manufacturing efficiency. It has built a diversified global presence across the US, South America, Europe, the Middle East, Africa, and Asia-Pacific. As per the F&S Report, the company is among the largest producers of food-grade iron phosphate globally and, in 2024, one of India’s largest exporters of mineral ingredients by volume. It is also the only Indian player and one of nine globally with CEP and written confirmation for calcium carbonate API in the EU. The company is recognized as a pioneer in developing liposomal ingredients to enhance nutrient absorption. Since its inception in 1989, the company has scaled its portfolio to over 100 products. It operates through two primary verticals such: (1) Pharmaceutical, Food & Nutrition Ingredients, comprising refined mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, and copper used as excipients, APIs, and nutritional fortification agents; and (2) Specialty Ingredients, housed under Subsidiary SNPL, offering micronutrient premixes, encapsulated ingredients, liposomal and spray-dried ingredients, granulated minerals, and triturated blends for applications in dietary supplements, infant and clinical nutrition, functional foods, and FMCG. As of Q1FY26, the company has served over 1,100 customers, including Pfizer, Intas, Mankind, Merck, Alembic, Aurobindo, Cadila, Micro Labs, IMCD, and Danone, with strong, long-term relationships. Repeat business contributed ~78–83% of revenue in recent years, underscoring a sticky customer base. Manufacturing infrastructure comprises three facilities in Vadodara (combined capacity: 65,579 MT) and an additional facility in Ireland, acquired in May 2025 as part of the NSS acquisition. A strong emphasis on R&D underpins its competitive positioning, supported by two dedicated R&D centres and a 41-member technical team.

Objective of the Sudeep Pharma Ltd IPO

The net proceeds from the fresh issue will be used towards the following purposes:

  • Capital expenditure towards procurement of machinery for production line located at Nandesari Facility I;
  • General corporate purposes.

Rationale To Sudeep Pharma Ltd IPO

Market Leadership with a Diversified Portfolio in a High-Barrier Industry

The company is one of the leading manufacturers of pharmaceutical, food, nutrition, and specialty ingredients, with a production volume of approximately 1.2 million metric tons as of Q1FY26, and an emphasis on mineral-based products, including iron phosphate, according to the F&S Report.  A comprehensive product portfolio reinforces the company’s market leadership. From an early focus on excipients, they have broadened their product range to include specialized ingredient solutions. As of Q1FY26, they have a diverse portfolio of over 100 products. According to the F&S Report, India’s food and nutritional ingredients market is expanding rapidly, driven by rising health awareness, higher disposable incomes, and growing demand for fortified foods, dietary supplements, and functional beverages. In the pharmaceutical space, excipients, despite being low-cost components, remain critical to product stability and efficiency, with the Indian excipient market offering significant headroom due to cost-efficient raw materials, skilled labour, and faster adoption of new technologies. The industry’s stringent regulatory requirements, long development cycles, and high R&D investment create substantial entry barriers, favouring established players with accredited facilities, proven regulatory compliance, and optimized manufacturing capabilities. Supported by its strong regulatory track record, broad product capabilities, and entrenched market position, the company is well placed to capitalize on sustained growth across the pharmaceutical, food, and nutrition ingredient markets.

Deep Global Customer Relationships Enhancing Revenue Visibility

The company’s diversified, globally entrenched customer base is a strong pillar of its investment appeal. As of Q1FY26, it has served over 1,100 customers across the pharmaceutical, food, nutrition, and FMCG sectors, including more than 40 blue-chip multinational companies and 14 global Fortune 500 clients. Long-standing relationships with marquee names such as Pfizer, Intas, Mankind, Merck, Alembic, Aurobindo, Cadila, IMCD, Micro Labs, and Danone underscore the company’s credibility, product quality, and regulatory strength. The depth of these partnerships is reflected in the stable contribution from key accounts ; its largest customer accounted for 8- 15% of revenues over FY23 and Q1FY26, and its top five customers have an average relationship tenure of over seven years. Such entrenched customer stickiness, combined with a broad geographic footprint, enhances revenue visibility, drives recurring business and provides a strong platform for scaling high-value specialty ingredients globally.

Valuation of Sudeep Pharma Ltd IPO

Sudeep Pharma is one of the largest manufacturers of excipients and speciality ingredients, catering to diverse industries. The company’s manufacturing facilities are approved by global institutions, including one approved by the USFDA, which has enabled a broader market reach. The company is in the process of establishing a manufacturing facility with 51,200 MT and ~71% of the current capacity to cater to the increasing demand. The company also aims to expand its speciality ingredients franchise through technology-led innovations in encapsulation, liposomal delivery, granulation, and spray drying. It continues to deepen penetration in global markets through regional sales offices in the US, Europe, the UK, and Latin America, coupled with stocking arrangements to strengthen last-mile delivery. Capacity augmentation across its Vadodara facilities and integration of the newly acquired Ireland unit will further support global scalability. The company is also increasing its R&D focus on particle engineering, nutrient bioavailability, shelf-life extension, and formulation efficiency enhancements to build high-value, application-specific ingredient platforms. The industry backdrop remains favourable, driven by growing demand for fortified foods, dietary supplements, functional beverages, and stable growth in pharmaceuticals and excipients. Rising global outsourcing of drug formulation to India, driven by higher costs in the US and Europe, further enhances long-term opportunities. With stringent regulatory processes creating high barriers for new entrants, established players like this company stand to benefit from market consolidation and increased wallet share among global customers. On the financial front, the company has demonstrated CAGR growth of 8%/46%/49% in Revenue/EBITDA/PAT between FY23–FY25, led by leadership in the niche segment and its future foray into high-growth businesses. Overall, the company’s strong regulatory credentials, diversified portfolio, innovation-led product pipeline, and expanding global reach position it for sustained revenue growth. At the upper price band of Rs. 593, the company is valued at a P/E multiple of 46.4x FY25 earnings. We, thus, recommend a “SUBSCRIBE” rating for this issue.

What is the Sudeep Pharma Ltd IPO?

The initial public offer (IPO) of Sudeep Pharma Ltd offers an early investment opportunity in Sudeep Pharma Ltd . A stock market investor can buy Sudeep Pharma Ltd IPO shares by applying in IPO before All Sudeep Pharma Ltd shares get listed at the stock exchanges. An investor could invest in Sudeep Pharma Ltd IPO for short term listing gain or a long term.

To apply for the Sudeep Pharma Ltd IPO through StoxBox one can apply from the website and also from the app. Click here

Sudeep Pharma Ltd IPO is opening on 21st Nov 2025.  Apply Now

The Lot Size of Sudeep Pharma Ltd IPO is 25 equity shares. Login to your account now.

The allotment Date for Sudeep Pharma Ltd IPO is 26th Nov 2025.  Login to your account now.

The listing Date for Sudeep Pharma Ltd IPO is 28th Nov 2025.  Login to your account now

In the Retail segment the minimum investment required is Rs. 14,825. Login to your account now

 In the Retail segment the maximum investment requirement is Rs. 1,92,725. Login to your account now

  • The company derives a substantial portion of its revenue from the top 5 customers. Any loss of such customers or a decline in demand may adversely impact the business.
  • The company has three manufacturing facilities and one R&D facility located in the single region of Vadodara, Gujarat. Any adverse developments in the area may impact operations.
  • The company relies on third-party suppliers for raw materials, including calcium carbonate, phosphoric acid, and sorbic acid. It may experience an unanticipated increase in raw material costs due to fluctuations in supply and demand across domestic and international markets, which may adversely impact operations.

The Sudeep Pharma Ltd IPO be credited to the account on allotment date which is 26th Nov 2025. Login to your account now 

The prospectus of Sudeep Pharma Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE